This may be due to the characteristic that neutrophils will undergo a “change” in immunogenicity from anti-tumorigenic to pro-tumorigenic with the development of cancer.[32] In early-stage melanomas, neutrophils will cross-present to CD8 + T cells to induce tumor-specific effector T cell responses, and eventually stimulate anti-tumor effects.[33] However, over time, the ability of neutrophils to participate in immune pathways decreases with cancer progression.[34] Thus, the specific role and mechanism of neutrophils in different stages of skin cancer need further exploration. The gene discussed is CD8A; the disease is melanoma.